Skip to main content Accessibility help
×
×
Home

The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy

  • Bato Lazarevic (a1), Clara Hammarström (a2), Jin Yang (a3), Hakon Ramberg (a1), Lien M. Diep (a4), Steinar J. Karlsen (a1) (a5), Omer Kucuk (a6), Fahri Saatcioglu (a3), Kristin A. Taskèn (a1) (a5) and Aud Svindland (a5) (a7)...
Abstract

Nutritionally relevant levels of genistein, the predominant isoflavone in soyabean associated with lower risk of prostate cancer (PCa), may modulate the expression of prostate tissue biomarkers associated with cancer prediction and progression. A phase 2 placebo-controlled, randomised, double-blind clinical trial was conducted in forty-seven Norwegian patients before prostatectomy. Intervention was 30 mg genistein or placebo capsules daily for 3–6 weeks. Luminal cells from malignant and benign glands were isolated with laser capture microdissection and the mRNA levels of androgen-related biomarkers (androgen receptor, NK3 homeobox 1, kallikrein-related peptide 4 (KLK4)) and cell cycle-related genes (p21 Waf1/Cip1 , p27 Kip1 , p53) were analysed with real-time semiquantitative PCR. Immunohistochemistry of androgen-, cell cycle-, proliferative- (Ki67 nuclear antigen), apoptotic- (B-cell CLL/lymphoma 2 (BCL-2) and BCL-2-associated X protein) and neuroendocrine differentiation-related biomarkers (neuron-specific enolase and cytoplasmic chromogranin A) was performed using tissue microarrays containing normal, Gleason grade 3 and grade 4 prostate tissues. There were no significant effects by genistein intervention on proliferation-, cell cycle-, apoptosis- or neuroendocrine biomarkers. Genistein intervention, however, significantly reduced the mRNA level of KLK4 in tumour cells (P = 0·033) and there was a non-significant reduction in androgen and cell cycle-related biomarkers, except for p27Kip1, whose expression in the nuclear compartment was increased. Genistein intervention modulated the expression of several biomarkers which may be related to PCa prediction and progression. The present study supports genistein as a chemopreventive agent in PCa. Further investigation is warranted in larger and longer-duration studies.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy
      Available formats
      ×
Copyright
Corresponding author
* Corresponding author: B. Lazarevic, fax +47 22935944, email bato.lazarevic@medisin.uio.no
References
Hide All
1 Madu, CO & Lu, Y (2010) Novel diagnostic biomarkers for prostate cancer. J Cancer 1, 150177.
2 Lopergolo, A & Zaffaroni, N (2009) Biomolecular markers of outcome prediction in prostate cancer. Cancer 115, 30583067.
3 Netto, GJ & Epstein, JI (2010) Theranostic and prognostic biomarkers: genomic applications in urological malignancies. Pathology 42, 384394.
4 Banerjee, S, Li, Y, Wang, Z, et al. (2008) Multi-targeted therapy of cancer by genistein. Cancer Lett 269, 226242.
5 Steiner, C, Arnould, S, Scalbert, A, et al. (2008) Isoflavones and the prevention of breast and prostate cancer: new perspectives opened by nutrigenomics. Br J Nutr 99E, Suppl. 1, ES78E108.
6 Lazarevic, B, Boezelijn, G, Diep, LM, et al. (2011) Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind phase 2 clinical trial. Nutr Cancer 63, 889898.
7 Ullmann, U, Metzner, J, Frank, T, et al. (2005) Safety, tolerability, and pharmacokinetics of single ascending doses of synthetic genistein (Bonistein) in healthy volunteers. Adv Ther 22, 6578.
8 Bonner, RF, Emmert-Buck, M, Cole, K, et al. (1997) Laser capture microdissection: molecular analysis of tissue. Science 278, 14811483.
9 Rubin, MA, Dunn, R, Strawderman, M, et al. (2002) Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26, 312319.
10 Davis, JN, Kucuk, O & Sarkar, FH (2002) Expression of prostate-specific antigen is transcriptionally regulated by genistein in prostate cancer cells. Mol Carcinog 34, 91101.
11 Lazarevic, B, Karlsen, SJ & Saatcioglu, F (2008) Genistein differentially modulates androgen-responsive gene expression and activates JNK in LNCaP cells. Oncol Rep 19, 12311235.
12 Bova, GS, Carter, BS, Bussemakers, MJ, et al. (1993) Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 53, 38693873.
13 Bieberich, CJ, Fujita, K, He, WW, et al. (1996) Prostate-specific and androgen-dependent expression of a novel homeobox gene. J Biol Chem 271, 3177931782.
14 Abate-Shen, C, Shen, MM & Gelmann, E (2008) Integrating differentiation and cancer: the Nkx3·1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation 76, 717727.
15 Gurel, B, Ali, TZ, Montgomery, EA, et al. (2010) NKX3·1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol 34, 10971105.
16 Klokk, TI, Kilander, A, Xi, Z, et al. (2007) Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer. Cancer Res 67, 52215230.
17 Veveris-Lowe, TL, Lawrence, MG, Collard, RL, et al. (2005) Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr Relat Cancer 12, 631643.
18 Kobayashi, T, Nakata, T & Kuzumaki, T (2002) Effect of flavonoids on cell cycle progression in prostate cancer cells. Cancer Lett 176, 1723.
19 Pinski, J, Wang, Q, Quek, ML, et al. (2006) Genistein-induced neuroendocrine differentiation of prostate cancer cells. Prostate 66, 11361143.
20 Navone, NM, Troncoso, P, Pisters, LL, et al. (1993) p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85, 16571669.
21 Janicke, RU, Sohn, D, Essmann, F, et al. (2007) The multiple battles fought by anti-apoptotic p21. Cell Cycle 6, 407413.
22 Shiraishi, T, Watanabe, M, Muneyuki, T, et al. (1998) A clinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancers. Urol Int 61, 9094.
23 Li, J, Yen, C, Liaw, D, et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 19431947.
24 Medema, RH, Kops, GJ, Bos, JL, et al. (2000) AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404, 782787.
25 Li, Y & Sarkar, FH (2002) Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 8, 23692377.
26 Kikuno, N, Shiina, H, Urakami, S, et al. (2008) Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int J Cancer 123, 552560.
27 Shen, JC, Klein, RD, Wei, Q, et al. (2000) Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Mol Carcinog 29, 92102.
28 Barbisan, F, Mazzucchelli, R, Santinelli, A, et al. (2010) Expression of prostate stem cell antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer. Histopathology 57, 572579.
29 Krajewska, M, Krajewski, S, Epstein, JI, et al. (1996) Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148, 15671576.
30 Taplin, ME, George, DJ, Halabi, S, et al. (2005) Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology 66, 386391.
31 Kamiya, N, Akakura, K, Suzuki, H, et al. (2003) Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. Eur Urol 44, 309314, discussion 314.
32 Hvamstad, T, Jordal, A, Hekmat, N, et al. (2003) Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol 44, 215221.
33 Hillman, GG, Wang, Y, Kucuk, O, et al. (2004) Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol Cancer Ther 3, 12711279.
34 Raffoul, JJ, Banerjee, S, Che, M, et al. (2007) Soy isoflavones enhance radiotherapy in a metastatic prostate cancer model. Int J Cancer 120, 24912498.
35 Singh-Gupta, V, Zhang, H, Yunker, CK, et al. (2010) Daidzein effect on hormone refractory prostate cancer in vitro and in vivo compared to genistein and soy extract: potentiation of radiotherapy. Pharm Res 27, 11151127.
36 Nakamura, H, Wang, Y, Kurita, T, et al. (2011) Genistein increases epidermal growth factor receptor signaling and promotes tumor progression in advanced human prostate cancer. PLoS One 6, e20034.
37 El Touny, LH & Banerjee, PP (2009) Identification of a biphasic role for genistein in the regulation of prostate cancer growth and metastasis. Cancer Res 69, 36953703.
38 Lakshman, M, Xu, L, Ananthanarayanan, V, et al. (2008) Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Res 68, 20242032.
39 Gu, Y, Zhu, CF, Dai, YL, et al. (2009) Inhibitory effects of genistein on metastasis of human hepatocellular carcinoma. World J Gastroenterol 15, 49524957.
40 Setchell, KD, Brown, NM, Zhao, X, et al. (2011) Soy isoflavone phase II metabolism differs between rodents and humans: implications for the effect on breast cancer risk. Am J Clin Nutr 94, 12841294.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

British Journal of Nutrition
  • ISSN: 0007-1145
  • EISSN: 1475-2662
  • URL: /core/journals/british-journal-of-nutrition
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed